- Question from Mertz: In light of continuing concerns about long-time use of Zometa in the metastatic setting, was there any update about a possible new drug that might have fewer side effects called denosumab?
- Answers - Andrew D. Seidman, M.D. It is an exciting time in our understanding of the biology and treatment and prevention of bone metastases. Denosumab (brand name: Prolia) is an agent that is emerging as a powerful tool against osteoporosis in osteolytic metastases from breast cancer, prostate cancer, and multiple myeloma. While it has a favorable safety profile as the questioner implied, it is not without possible toxicities. It was recently approved by the FDA for treatment of osteoporosis and is considered for its role in treating bone metastases.
On Thursday, June 10, 2010, our Ask-the-Expert Online Conference was called Updates from the 2010 ASCO Annual Meeting. Andrew Seidman, M.D. and Beth Baughman DuPree, M.D., F.A.C.S. answered your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.